European growth fund

Sofinnova Crossover II

Public fund record: capital, investment focus and sources.

Growth fund based in Paris, managed by Sofinnova Partners. €725m reported at final close (source published November 2026).

Late-stage life sciences crossover fund backing clinical-stage biopharma and medtech companies, about 15 companies, primarily in Europe.

Fund details

Status
Final Close
Reported amount
€725m
Manager
Sofinnova PartnersFounded 1972Company size 11–50
Headquarters
Paris, France
Stages
Growth
Sectors
Health & Bio
Investment geography
Primarily Europe, selective investments in the US and other markets
Source published
November 2026

Amounts come from the linked public source. A first close is not the final fund size, and a reported close does not confirm that the fund is investing now. Headquarters describe where the manager is based, not where it invests.